Telomir Pharmaceuticals, Inc. (NASDAQ:TELO - Free Report) - Equities researchers at Zacks Small Cap issued their FY2024 earnings per share (EPS) estimates for shares of Telomir Pharmaceuticals in a report released on Thursday, November 21st. Zacks Small Cap analyst B. Sorensen expects that the company will earn ($0.54) per share for the year. The consensus estimate for Telomir Pharmaceuticals' current full-year earnings is ($0.54) per share. Zacks Small Cap also issued estimates for Telomir Pharmaceuticals' Q4 2024 earnings at ($0.05) EPS, Q1 2025 earnings at ($0.06) EPS, Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.23) EPS, Q1 2026 earnings at ($0.03) EPS, Q2 2026 earnings at ($0.04) EPS, Q3 2026 earnings at ($0.06) EPS and FY2026 earnings at ($0.18) EPS.
Telomir Pharmaceuticals Stock Up 5.9 %
Shares of Telomir Pharmaceuticals stock traded up $0.25 on Monday, hitting $4.49. The company had a trading volume of 243,703 shares, compared to its average volume of 81,497. The stock has a 50-day moving average of $5.03 and a 200-day moving average of $5.00. Telomir Pharmaceuticals has a twelve month low of $3.11 and a twelve month high of $20.72.
Hedge Funds Weigh In On Telomir Pharmaceuticals
A number of large investors have recently added to or reduced their stakes in TELO. Beaird Harris Wealth Management LLC raised its holdings in shares of Telomir Pharmaceuticals by 212.9% in the second quarter. Beaird Harris Wealth Management LLC now owns 14,623 shares of the company's stock valued at $70,000 after purchasing an additional 9,950 shares during the last quarter. Bank of New York Mellon Corp bought a new position in Telomir Pharmaceuticals in the second quarter valued at $241,000. Suncoast Equity Management increased its stake in Telomir Pharmaceuticals by 109.9% in the 3rd quarter. Suncoast Equity Management now owns 51,194 shares of the company's stock valued at $329,000 after buying an additional 26,803 shares during the last quarter. Barclays PLC lifted its position in Telomir Pharmaceuticals by 325.1% during the 3rd quarter. Barclays PLC now owns 7,018 shares of the company's stock worth $45,000 after buying an additional 5,367 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Telomir Pharmaceuticals by 259.8% during the 3rd quarter. Geode Capital Management LLC now owns 238,737 shares of the company's stock worth $1,533,000 after buying an additional 172,382 shares during the last quarter.
About Telomir Pharmaceuticals
(
Get Free Report)
Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.
Recommended Stories
Before you consider Telomir Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telomir Pharmaceuticals wasn't on the list.
While Telomir Pharmaceuticals currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
